Sanofi (SNY)
NASDAQ: SNY · IEX Real-Time Price · USD
48.54
-1.05 (-2.12%)
At close: Jul 2, 2024, 4:00 PM
45.98
-2.56 (-5.27%)
After-hours: Jul 2, 2024, 4:57 PM EDT
Sanofi Employees
Sanofi had 86,088 employees as of December 31, 2023. The number of employees decreased by 5,485 or -5.99% compared to the previous year.
Employees
86,088
Change (1Y)
-5,485
Growth (1Y)
-5.99%
Revenue / Employee
$599,438
Profits / Employee
$69,696
Market Cap
121.63B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 86,088 | -5,485 | -5.99% |
Dec 31, 2022 | 91,573 | -3,869 | -4.05% |
Dec 31, 2021 | 95,442 | -3,970 | -3.99% |
Dec 31, 2020 | 99,412 | -997 | -0.99% |
Dec 31, 2019 | 100,409 | -3,817 | -3.66% |
Dec 31, 2018 | 104,226 | -2,340 | -2.20% |
Dec 31, 2017 | 106,566 | -293 | -0.27% |
Dec 31, 2016 | 106,859 | -2,230 | -2.04% |
Dec 31, 2015 | 109,089 | 1,702 | 1.58% |
Dec 31, 2014 | 107,387 | -4,741 | -4.23% |
Dec 31, 2013 | 112,128 | 154 | 0.14% |
Dec 31, 2012 | 111,974 | -1,745 | -1.53% |
Dec 31, 2011 | 113,719 | 12,144 | 11.96% |
Dec 31, 2010 | 101,575 | -3,292 | -3.14% |
Dec 31, 2009 | 104,867 | 6,654 | 6.78% |
Dec 31, 2008 | 98,213 | -1,282 | -1.29% |
Dec 31, 2007 | 99,495 | -794 | -0.79% |
Dec 31, 2006 | 100,289 | 3,108 | 3.20% |
Dec 31, 2005 | 97,181 | 742 | 0.77% |
Dec 31, 2004 | 96,439 | 63,353 | 191.48% |
Dec 31, 2003 | 33,086 | 650 | 2.00% |
Dec 31, 2002 | 32,436 | 1,922 | 6.30% |
Dec 31, 2001 | 30,514 | 1,314 | 4.50% |
Dec 31, 2000 | 29,200 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Elevance Health | 104,900 |
Medtronic | 95,000 |
Pfizer | 88,000 |
Cigna | 72,500 |
Boston Scientific | 48,000 |
Stryker | 26,700 |
Gilead Sciences | 18,000 |
Intuitive Surgical | 13,676 |
SNY News
- 18 minutes ago - EU approves Sanofi's Dupixent for 'smoker's lungs' - Reuters
- 29 minutes ago - Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD - GlobeNewsWire
- 1 day ago - Sanofi eyes German insulin investment of up to $1.6 bln, source says - Reuters
- 1 day ago - Sanofi eyes investment of up to $1.6 bln in Germany, Handelsblatt says - Reuters
- 5 days ago - German vaccine panel endorses Astra-Sanofi's RSV shot for infants - Reuters
- 6 days ago - Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM - GlobeNewsWire
- 6 days ago - Sanofi-backed Formation Bio raises $372 million in late-stage funding round - Reuters
- 6 days ago - Sanofi Looks To Sell $20B Icy Hot Division: Likely Bidders Include Advent, PAI Partners, Blackstone, CVC - Benzinga